The incidence of clozapine-induced leukopenia in patients with schizophrenia at Srinagarind Hospital

Journal of the Medical Association of Thailand

Volumn 90, Issue 10, 2007, Pages 2175-2180

  Maskasame, Sarin ^a   Krisanaprakornkit, Thawatchai ^a   Khiewyoo, Jiraporn ^b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Agranulocytosis; Clozapine; Incidence density; Incidence rate; Leukopenia; Neutropenia

Indexed keywords

CLOZAPINE;

ADOLESCENT; ADULT; AGED; AGRANULOCYTOSIS; BLOOD CELL COUNT; BLOOD SAMPLING; CLINICAL PRACTICE; DEMOGRAPHY; DESCRIPTIVE RESEARCH; FEMALE; HUMAN; INCIDENCE; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL PATIENT; NEUTROPENIA; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; REVIEW; SAMPLE SIZE; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; INCIDENCE; LEUKOPENIA; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; THAILAND;

EID: 35848965715     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. thed. Philadelphia: Lippincott Williams & Wilkins; 2003: 471-504.
2. The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Clozapine Study Group. Br J Psychiatry 1993; 163: 150-4.
3. Donaldson SR, Gelenberg AJ, Baldessarini RJ. The pharmacologic treatment of schizophrenia: a progress report. Schizophr Bull 1983; 9: 504-27.
4. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C. Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980; 6: 70-87.
5. Hippius H. A historical perspective of clozapine. J Clin Psychiatry 1999; 60(Suppl 12): 22-3.
6. Udomrath P. Incidence of leukopenia and agranulocytosis in 239 Thai patients treated with clozapine. J Psychiatr Assoc Thai 2000; 45: 229-36.
7. Dev VJ, Krupp P. Adverse event profile and safety of clozapine. Rev Contemp Pharmacother 1995; 6: 197-208.
8. Kane JM. Treatment of schizophrenia. Schizophr Bull 1987; 13: 133-56.
9. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41: 850-4.
10. Wren P, Frizzell LA, Keltner NL, Wright AV. Three potentially fatal adverse effects of psychotropic medications. Perspect Psychiatr Care 2003; 39: 75-81.
11. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59(Suppl 3): 3-7.
12. Hummer M, Kurz M, Barnas C, Saria A, Fleischhacker WW. Clozapine-induced transient white blood count disorders. J Clin Psychiatry 1994; 55: 429-32.
13. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990; 47: 945-8.
14. Jungi WF, Fischer J, Senn HJ, Hartlapp J, Poldinger W, Kunz H, et al. [Frequent cases of agranulocytosis due to clozapin (leponex) in eastern Switzerland]. Schweiz Med Wochenschr 1977; 107: 1861-4.
15. Fischer V, Haar JA, Greiner L, Lloyd RV, Mason RP. Possible role of free radical formation in clozapine (clozaril) induced agranulocytosis. Mol Pharmacol 1991; 40: 846-53.
16. Pisciotta AV, Konings SA, Ciesemier LL, Cronkite CE, Lieberman JA. Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis. J Lab Clin Med 1992; 119: 254-66.
17. Safferman AZ, Lieberman JA, Alvir JM, Howard A. Rechallenge in clozapine-induced agranulocytosis. Lancet 1992; 339: 1296-7.
18. Gerson SL, Arce C, Meltzer HY. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 1994; 86: 555-61.
19. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine induced agranulocytosis. N Engl J Med 1993;329:162-7.
20. Tangtrakul C, Mongkulsagoonrit W, Chongkulkaew A, Leenakhanit M, Hoondee U. Retrospective study of the factor associated with agranulocytosis in clozapine recipients following clozapine administration at Somdetchaopraya Hospital. J Ment Health Thai 2002; 10: 89-98.
21. Chantarasak S. Study of safety and outcomes of clozapine for treatment of schizophrenia at Srithanya Hospital. J Ment Health Thai 2001; 9: 81-9.
22. Thiengburanathum T, Wisutikul J, Piyatrakul N. White blood cell (WBC) count monitoring and incidence of agranulocytosis in patients taking clozapine. Bull Dept Med Serv 2003; 28: 18-23.
23. Thai Food and Drug Administration, Ministry of Public Health, Thailand. Clozaril antipsychotics. No. 1C90/42(N) ed., 2001.
24. Data of psychiatric outpatients at Srinagarind Hospital. 10 common diseases during the year 2003-2005. Khon Kaen, Thailand: Srinagarind Hospital Information Management System; 2006.
25. Alphs LD, Anand R. Clozapine: the commitment to patient safety. J Clin Psychiatry 1999; 60(Suppl 12): 39-42.
26. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169: 483-8.
27. Bender JK. FDA approves reduced clozapine monitoring: increased patient access versus increased risk. Psychiatric Times. URL: http://psychiatrictimes. com/p980513.html (Cited 2006 Jan 5).